How much does Daratumumab cost?

Daratumumab is a monoclonal antibody drug used to treat multiple myeloma (Multiple Myeloma). It has revolutionized the treatment of this leukemia. Multiple myeloma is a bone marrow malignancy that often causes abnormal immunoglobulins (immunoglobulins, a type of antibody) to build up in the blood, disrupting normal immune system function.

daratumumab has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The price is about more than 5,000. Medical insurance reimbursement must meet the reimbursement conditions. For specific prices and medical insurance policies, please consult the local hospital pharmacy or medical insurance bureau. Currently, there is only the original drug of daratumumab in foreign countries. The cheaper one is the Turkish original drug, which costs around 5,000. The ingredients and efficacy are consistent with the domestic original drug.

Daratumumab is unique in that it recognizes and binds to theCD38 receptor on the surface of abnormally proliferating plasma cells in patients with multiple myeloma. By binding to the CD38 receptor, daratumumab prompts the immune system to attack and kill these abnormal plasma cells, thereby alleviating disease and improving survival.

The research and development of this drug is a landmark achievement because multiple myeloma has historically been a difficult-to-treat form of leukemia, with limited treatment options for many patients. The emergence of daratumumab not only provides patients with more treatment options, but also improves their quality of life. In addition, it has shown potential in the treatment of other leukemia and lymphoma types.

However, daratumumab is not without side effects. Common adverse reactions include infection, anemia, thrombocytopenia, fatigue, etc. Therefore, when using this drug, doctors will weigh the risks and benefits based on the patient's specific situation to ensure the best possible treatment.

xa0